Molecular structure of AZD8055, CAS Number: 1009298-09-2
AZD8055 (CAS 1009298-09-2)
See product citations (12)
Alternate Names:
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
Application:
AZD8055 is an mTOR kinase inhibitor
CAS Number:
1009298-09-2
Purity:
≥98%
Molecular Weight:
465.54
Molecular Formula:
C25H31N5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD8055 is a selective ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. It inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. It also fully inhibits the rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1, resulting in significant inhibition of cap-dependent translation. In H838 and A549 cells, AZD8055 inhibits proliferation and induces autophagy.
AZD8055 (CAS 1009298-09-2) References
- AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. | Chresta, CM., et al. 2010. Cancer Res. 70: 288-98. PMID: 20028854
- Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. | Sini, P., et al. 2010. Autophagy. 6: 553-4. PMID: 20364113
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. | Houghton, PJ., et al. 2012. Pediatr Blood Cancer. 58: 191-9. PMID: 21337679
- mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. | Jiang, Q., et al. 2011. Cancer Res. 71: 4074-84. PMID: 21540234
- Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. | Huang, S., et al. 2011. J Biol Chem. 286: 40002-12. PMID: 21949121
- The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. | Willems, L., et al. 2012. Leukemia. 26: 1195-202. PMID: 22143671
- Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Holt, SV., et al. 2012. Cancer Res. 72: 1804-13. PMID: 22271687
- Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. | Renshaw, J., et al. 2013. Clin Cancer Res. 19: 5940-51. PMID: 23918606
- HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. | English, DP., et al. 2013. Gynecol Oncol. 131: 753-8. PMID: 24012800
- Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. | Preuss, E., et al. 2013. J Biol Chem. 288: 35287-96. PMID: 24133218
- Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. | Zeng, JY., et al. 2014. Mol Cancer Ther. 13: 37-48. PMID: 24233399
- AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. | Hu, M., et al. 2014. Oncol Rep. 31: 649-56. PMID: 24297300
- Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. | Sharma, S., et al. 2014. Mol Oncol. 8: 469-82. PMID: 24444656
- Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. | Jordan, NJ., et al. 2014. Breast Cancer Res. 16: R12. PMID: 24457069
- The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. | Pétigny-Lechartier, C., et al. 2017. Mol Cancer Ther. 16: 102-115. PMID: 27980105
- Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. | Khan, S., et al. 2023. Cell Death Discov. 9: 1. PMID: 36588105
Inhibitor of:
β-defensin 133, 1500010J02Rik, 1700020N15Rik, 1700021C14Rik, 2700089E24Rik, 4E-BP1, 4E-BP2, 4E-BP3 (EIF4EBP3), 5430416O09Rik, ACSVL4, ACTR-I, AMIGO3, ANKRD17, ARKL1_Arkadia 2, ARMC10, ARMCX2, ASCC1, Atg10, Atg3, BC052486, BC052688, BC053393, BC055107, BC055324, BC057022, BC057170, Bcl-7b, BKS, BRI3, BRSK2, C10orf122, C11orf10_1810006K21Rik, C11orf55, C11orf71, C11orf75_BC017612, C12orf29, C130050O18Rik, C14orf145, C14orf162, C14orf182, C15orf39, C19orf53, C1orf14_1700012A16Rik, C1orf86, C1sb, C20orf151, C22orf32, C2orf15, C2orf29_D1Bwg0212e, C3orf54, C6orf106_D17Wsu92e, CARD11, CASC1, CCDC151, CCDC167, CCDC22, CCDC34, CCDC51, Cdc27, Centaurin γ3, COTE1, CREBL2, CXorf59, D1Ertd622e, D6Mm5e, D830030K20Rik, Daf2, DEPDC6, DEPTOR, DOCK 4, E230028L10Rik, E2F-5, E2F-6, EG231736, EG436188, EG625464, EG625480, EG635895, ENX-1, Eos, EPSTI1, ESX1, F8A2, FAM131C, FAM169B, FAM22B, FAM23A, FAM23B, FAM25G, FAM32A, FAM81A, FAM98C, FASTKD1, FBL22_Fbxl22, FBXW18, fizzy-related protein, FLJ11506, FLJ31818, FOXJ3, FOXP3, FRBZ1, FYTTD1, Gab 2, GADD 45β, GATSL2, GATSL3, Gln3, GLT1D1, GPN2, GRB10, GSBS, hamartin, HCNP, HPV18 E7, IER5L, IF3, Imp3, IRS-1, IZUMO4, KIAA1609, KPI-2, KRTAP25-1, L-Myc, LAMTOR4, LBX1, LIN-31, LIN-39, LNP1, LOC646864, LOC728181, LOC728256, LOC729174, LOC729974, LOC730018, LRBA, LRRC10B, LRRC53, Mam1, MAST4, MGRN1, MIOS, MIS12, MS4A3, MS4A4E, MS4A5, MS4A8B, MST-4, mTOR, NanogNB, NARF, NBR1, NHSL2, NICE4, NKIAMRE, NKR-P1F, NumbL, Olfr372, Olfr549, Olfr632, Olr74, OTTMUSG00000010694, OTTMUSG00000016785, OTTMUSG00000019256, P15RS, p49/STRAP, p52 S6 kinase, p70 S6 kinase β, PARD3A, Pericentrin 2, PHLDA3, Pira2, PISD, Plb2, Podocin, POM121L12, PRAS40, PRIC285, Protor-2, PRR5, Rae-1γ, REDD-2, Ribosomal Protein S6, RIFF, RIMKLA, RIOK1, RN-tre, rolled, RPS6KL1, RREB1, Rsk-1, RUSC1, S-100A10, SAMC, SCAI, Scpppq1, scute, SLC38A9, SMG1, SNED1, SPATA19, SPDYE2L, SSXB1, Ste20 (sterile 20) Serine/Threonine Kinase (STK), Svs3b, Svs5, SZT2, TATDN3, TBC1D10C, TBC1D16, TBC1D3H, TBC1D7, TEF-4, TESSP5, TEX14, TEX19.2, TINAGL1, Tip41, TLCD2, TMEM186, Tollip, Tomm20l, Tor1, Tor2, TORC1, TRIM46, TRIQK, TSPY3, TSSC1, TTP-αL, tuberin, UBXD3, V1RE4, V1RH16, V1RH20, V1RH21, V1RH3, WBP2, WBSCR9, WDR75, Wee 1, Ypk2, ZIK1, ZMAT4, ZNF492, ZNF514, ZNF728, and ZPR1.Activator of:
ARP-1, B7-H4, BTNL10, Btnl6, CEP41, cyclin J, Dengue Virus, Dynlt3, E130309D14Rik, E130311K13Rik, EDF1, EF-1 ε1, EG434729, EG434881, eIF4E2, Erd2, eyes absent, GABARAPL2, GOLGA6L, IFT43, IFT46, ILKAP, LARP1, Mad 1, MLE, MLSN1, NPRL3, Pep12, Pex13p, Pex14p, Pex7p, PROT, PRRG1, Rictor, SLUG, Sly1, SRP68, STCH, TELO2, Tlg2, TMEM127, TORC2, TRIML2, TTI1, Vam3, and WDFY2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD8055, 10 mg | sc-364424 | 10 mg | $163.00 | |||
AZD8055, 50 mg | sc-364424A | 50 mg | $352.00 |